Big Pharma trio backs cancer startup; AB jumps on ALS data; Shire founder oversees AIM listing

Nick Paul Taylor In this week's EuroBiotech Report, Metabomed celebrated adding Pfizer to a list of investors that already featured the VC units of Merck KGaA and Boehringer Ingelheim. ...

Struggling Eisai gets FDA approval for cancer drug Halaven for liposarcoma

Eric Palmer Japan's Eisai got a much-needed boost on Thursday when the FDA approved its cancer drug, Halaven, for treatment of liposarcoma for patients in which the cancer has advanced ...

Venetoclax grabs third FDA ‘breakthrough’ for blood cancer

Alok Saboo AbbVie and Roche's venetoclax has received yet another accelerated review from the FDA–this time in patients with the most common type of acute leukemia. FierceBiotech ...

Langer-backed biotech reboots with $38M, new name and new cancer drug tech

John Carroll Four-year-old biotech Blend Therapeutics, launched with the scientific backing of MIT's Robert Langer and colleagues, is jettisoning its one-time lead drug program ...

Anti-PD-1? Well, no, says Medivation as a partial hold forces a halt to ‘pivotal’ cancer study

John Carroll When Medivation bought out the rights to CureTech's pidilizumab, it trumpeted its entry into checkpoint inhibition with a drug that aimed right at PD-1, unleashing ...

UPDATED: OncoMed hits the brakes on PhII pancreatic cancer trial, shares plummet

John Carroll OncoMed slammed the brakes on a Phase II study of the cancer stem cell drug tarextumab, citing worsening response rates in the drug arm for pancreatic cancer, with red ...

U.K.’s NICE says yes to Opdivo for advanced skin cancer

Eric Palmer Last month the U.K. drug cost watchdog nixed Bristol-Myers Squibb's immunotherapy Opdivo for use against lung cancer, saying in draft guidance that it just cost too ...

ArGEN-X pulls in €16M to push cancer, autoimmune programs to clinical POC

Nick Paul Taylor Federated Investors has bought an 8.6% stake in arGEN-X. The deal sees arGEN-X sell shares worth €16 million ($ 17.5 million) to the major U.S. asset manager, ...

Surrounded by top scientists, Biden hustles up support for accelerated cancer R&D

John Carroll Vice President Joe Biden used the spotlight at the World Economic Forum in Davos to gather together some of the top players in drug R&D and highlight his push to speed ...

China’s BeiGene pitches a $150M IPO to fund its cancer pipeline

Damian Garde Chinese biotech BeiGene is hoping to trade on the Nasdaq, filing for an IPO worth more than $ 150 million to support its pipeline of targeted cancer drugs. FierceBiotech ...

AbbVie and Roche’s cancer drug snags another ‘breakthrough’ tag

Damian Garde AbbVie and Roche's cancer drug venetoclax, awaiting FDA approval, picked up another breakthrough therapy nod from the agency for its potential as part of a combination ...

Eisai scores FDA priority review for bigger Lenvima use in kidney cancer

Tracy Staton Eisai's thyroid cancer drug Lenvima stepped into the FDA's fast lane for a new use. FiercePharma News
Page 1 of 2312345...1020...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS